Live News EQUITY L impact Jun 30, 2026, 02:35 PM UTC

HC Wainwright & Co. Maintains Buy on BioCryst Pharma, Maintains $32 Price Target

HC Wainwright & Co. analyst Andrew S. Fein maintains BioCryst Pharma (NASDAQ: BCRX ) with a Buy and maintains $32 price target.

SQUAWKNEWS Updated Jun 30, 2026, 02:35 PM UTC

HC Wainwright & Co. analyst Andrew S.

Fein maintains BioCryst Pharma (NASDAQ: BCRX ) with a Buy and maintains $32 price target.